Time to Reconsider Albireo Pharma Inc (NASDAQ:ALBO) After More Short Sellers?

April 17, 2018 - By Darrin Black

The stock of Albireo Pharma Inc (NASDAQ:ALBO) registered an increase of 156.56% in short interest. ALBO’s total short interest was 132,900 shares in April as published by FINRA. Its up 156.56% from 51,800 shares, reported previously. With 74,900 shares average volume, it will take short sellers 2 days to cover their ALBO’s short positions. The short interest to Albireo Pharma Inc’s float is 3.75%.

The stock decreased 0.39% or $0.13 during the last trading session, reaching $32.97. About 25,452 shares traded. Albireo Pharma, Inc. (NASDAQ:ALBO) has risen 43.49% since April 17, 2017 and is uptrending. It has outperformed by 31.94% the S&P500.

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders in the United States. The company has market cap of $392.25 million. The Company’s lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. It currently has negative earnings. The companyÂ’s clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption.

Albireo Pharma, Inc. (NASDAQ:ALBO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: